Kiromic BioPharma, Inc. (KRBP) Stock Analysis

Kiromic BioPharma, Inc. (KRBP) Healthcare & Pipeline Overview

Kiromic BioPharma, Inc. is an AI-driven biotechnology company specializing in allogeneic Gamma Delta T cell therapies targeting solid tumors. Their pipeline includes ALEXIS-ISO-1 and ALEXIS-PRO-1, novel cell therapies designed to enhance the natural potency of Gamma Delta T cells. The company operates in the competitive biotechnology sector.

What Is the Investment Thesis for KRBP?

Kiromic BioPharma's investment thesis centers on its innovative approach to cancer treatment using allogeneic Gamma Delta T cell therapies. The company's focus on solid tumors, a significant unmet medical need, presents a substantial market opportunity. Key value drivers include the successful development and commercialization of ALEXIS-ISO-1 and ALEXIS-PRO-1. Growth catalysts include advancing these product candidates through clinical trials and securing partnerships for manufacturing and distribution. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. With a market capitalization of $0.00B and a P/E ratio of -0.17, the company's valuation reflects its early-stage development.

Based on FMP financials and quantitative analysis

KRBP Key Highlights

Kiromic BioPharma is focused on developing allogeneic Gamma Delta T cell therapies for solid tumors.

• Lead product candidates include ALEXIS-ISO-1 targeting Isomesothelin and ALEXIS-PRO-1 targeting PD-L1.
• The company leverages artificial intelligence to enhance its cell therapy development process.
• Kiromic has established strategic alliances and licensing agreements to support its research and development efforts.
• The company's therapies aim to exploit the natural potency of Gamma Delta T cells to improve cancer treatment outcomes.

Who Are KRBP's Competitors?

KRBP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are KRBP's Key Strengths?

Innovative AI-driven platform for cell therapy development.

• Focus on allogeneic Gamma Delta T cells, which may offer advantages over alpha-beta T cells.
• Strategic alliances and licensing agreements.
• Experienced management team with expertise in cell therapy and immuno-oncology.

What Are KRBP's Weaknesses?

Early-stage development with no approved products.

• Limited financial resources.
• High risk of clinical trial failures.
• Dependence on strategic alliances for manufacturing and distribution.

What Could Drive KRBP Stock Higher?

Clinical trial results for ALEXIS-ISO-1 in solid tumors.

• Clinical trial results for ALEXIS-PRO-1 in solid tumors.
• Expansion of Kiromic's AI-driven platform for new cell therapy targets.
• Strategic partnerships for manufacturing and distribution.
• Advancements in Gamma Delta T cell therapy technology.

What Are the Key Risks for KRBP?

Financial-distress signal — its Altman Z-Score of -35.96 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for ALEXIS-ISO-1 and ALEXIS-PRO-1.
• Regulatory hurdles and delays in obtaining FDA approval.
• Competition from established pharmaceutical companies and emerging biotech firms.
• Limited financial resources.
• Dependence on strategic alliances for manufacturing and distribution.

What Are the Growth Opportunities for KRBP?

• Advancing ALEXIS-ISO-1 through clinical trials represents a significant growth opportunity. Isomesothelin is overexpressed in several solid tumors, including mesothelioma, ovarian cancer, and lung cancer. Positive clinical data demonstrating the safety and efficacy of ALEXIS-ISO-1 could lead to accelerated regulatory approval and commercialization.
• The development of ALEXIS-PRO-1 targeting PD-L1 presents another key growth avenue. PD-L1 is a well-validated target in immuno-oncology, and ALEXIS-PRO-1 has the potential to address a broad range of solid tumors. Successful clinical trials could position ALEXIS-PRO-1 as a competitive alternative to existing PD-1/PD-L1 inhibitors. The global market for PD-1/PD-L1 inhibitors is estimated to be over $40 billion, indicating the significant commercial potential of ALEXIS-PRO-1.
• Expanding the application of Kiromic's AI-driven platform to discover and develop new cell therapies represents a long-term growth opportunity. The company's artificial intelligence capabilities can be leveraged to identify novel targets and design more effective cell therapies. This platform approach could lead to a pipeline of innovative products addressing a wide range of cancers and other diseases. The market for AI-driven drug discovery is projected to experience rapid growth in the coming years.
• Establishing strategic partnerships with pharmaceutical companies for manufacturing and distribution can accelerate the commercialization of Kiromic's products. Partnering with established players can provide access to resources and expertise that are critical for navigating the complex regulatory landscape and reaching a broader patient population. These partnerships can also generate upfront payments and milestone payments, providing additional funding for research and development.
• Exploring the potential of Gamma Delta T cell therapies in combination with other cancer treatments, such as chemotherapy and radiation therapy, represents a promising growth area. Combination therapies can potentially enhance the efficacy of existing treatments and improve patient outcomes. Kiromic can conduct clinical trials to evaluate the safety and efficacy of its cell therapies in combination with other modalities. Positive results could lead to new treatment paradigms and expanded market opportunities.

What Are KRBP's Competitive Advantages?

• Proprietary AI-driven platform for target identification and cell therapy design.
• Focus on allogeneic Gamma Delta T cells, which may offer advantages over alpha-beta T cells.
• Intellectual property protection for its cell therapy products and technologies.
• Strategic alliances and licensing agreements that provide access to resources and expertise.

What Does KRBP Do?

Founded in 2006 and headquartered in Houston, Texas, Kiromic BioPharma, Inc. is an artificial intelligence-driven allogeneic cell therapy company focused on developing innovative cancer treatments. The company leverages the natural potency of Gamma Delta T cells to target solid tumors, aiming to create more effective and accessible therapies. Kiromic's lead product candidates include ALEXIS-ISO-1, an allogeneic gamma delta CAR-T cell therapy targeting Isomesothelin, and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy targeting PD-L1. These therapies are designed to overcome the limitations of traditional cancer treatments by harnessing the unique properties of Gamma Delta T cells. Kiromic has established license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has a strategic alliance agreement with Leon Office (H.K.) Ltd. Kiromic BioPharma, Inc. was formerly known as Kiromic, Inc. and changed its name in December 2019, reflecting its commitment to advancing biopharmaceutical solutions.

What Products and Services Does KRBP Offer?

• Develops allogeneic Gamma Delta T cell therapies for solid tumors.
• Utilizes artificial intelligence to identify and validate therapeutic targets.
• Conducts preclinical and clinical research to evaluate the safety and efficacy of its therapies.
• Manufactures cell therapy products for clinical trials.
• Seeks regulatory approval for its therapies from the FDA and other regulatory agencies.
• Establishes strategic partnerships for manufacturing, distribution, and commercialization.

How Does KRBP Make Money?

• Develops and licenses allogeneic Gamma Delta T cell therapies.
• Generates revenue through strategic alliances and licensing agreements.
• May generate future revenue through product sales upon regulatory approval.
• Focuses on research and development of innovative cancer treatments.

What Industry Does KRBP Operate In?

Kiromic BioPharma operates within the rapidly evolving biotechnology industry, specifically in the cell therapy and immuno-oncology sectors. The market for cell therapies is experiencing significant growth, driven by advancements in genetic engineering and a deeper understanding of the immune system's role in fighting cancer. The competitive landscape includes established pharmaceutical companies and emerging biotech firms developing similar therapies. Kiromic's focus on allogeneic Gamma Delta T cells differentiates it from companies primarily focused on alpha-beta T cell therapies, potentially offering advantages in terms of scalability and safety.

Who Are KRBP's Key Customers?

• Patients with solid tumors who are candidates for cell therapy.
• Hospitals and cancer centers that administer cell therapies.
• Pharmaceutical companies that may partner with Kiromic for commercialization.
• Research institutions that collaborate with Kiromic on research and development.

Kiromic BioPharma, Inc. Financial Trajectory

Kiromic BioPharma, Inc. (KRBP) reported $0 in revenue for Q4 FY2024, based on the latest filing compared to the prior quarter. The company recorded a net loss of $6.5M, with diluted EPS of $-0.23. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, KRBP averaged $-0.19 in diluted EPS.

Company Profile

Kiromic BioPharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Pietro Bersani CPA,. KRBP has traded publicly since 2020.

Return on equity for Kiromic BioPharma, Inc. stands at 247.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.16 means current liabilities exceed short-term assets, a liquidity point worth watching.

Kiromic BioPharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -35.96 places it in the distress zone, a signal of elevated financial risk.

Kiromic BioPharma, Inc. has beaten Wall Street's EPS estimate in 3 of its last 3 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 81.6% above estimates on average.

The most recent 12 insider filings for Kiromic BioPharma, Inc. break down as 0 sales and 12 purchases. On net that is roughly 20K shares acquired (about $54K) — insiders putting money in tends to read as conviction.

KRBP Financials

KRBP Latest News

What Investors Ask About Kiromic BioPharma, Inc. (KRBP) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources